Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CDK4/6 Inhibitors”

90 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 90 results

Large-scale testing (Phase 3)WithdrawnNCT06585969
What this trial is testing

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerLuminal B+2 more
Danish Breast Cancer Cooperative Group
Not applicableUnknownNCT05814224
What this trial is testing

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Who this might be right for
Hormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more
Centro di Riferimento Oncologico - Aviano 164
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Early research (Phase 1)WithdrawnNCT04585724
What this trial is testing

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Who this might be right for
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8Metastatic Breast CarcinomaMetastatic Malignant Neoplasm in the Brain+1 more
Emory University
Not applicableUnknownNCT05051956
What this trial is testing

Evaluation of Geriatric Questionnaires to Predict Toxicities of CDK 4/6 Inhibitors in Older Breast Cancer Patients?

Who this might be right for
Can the Geriatric Questionnaires Predict Adverse Effects in Geriatric Breast Cancer Patients Treated With Cyclin-dependent Kinase 4 and 6 Inhibitors
Namik Kemal University 140
Not applicableActive Not RecruitingNCT06926088
What this trial is testing

Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 500
Not applicableLooking for participantsNCT07407439
What this trial is testing

Real-world Studies of CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 245
Not applicableStudy completedNCT05141240
What this trial is testing

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 4,650
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07173556
What this trial is testing

A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Qilu Pharmaceutical Co., Ltd. 96
Not applicableUnknownNCT04289974
What this trial is testing

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

Who this might be right for
Breast Cancer
Chinese Academy of Medical Sciences 100
Not applicableStudy completedNCT06624020
What this trial is testing

Learn About How Medicines Called CDK4/6 Inhibitors Are Used in People With Advanced or Metastatic Breast Cancer in Australia

Who this might be right for
Breast Neoplasms
Pfizer 1,128
Not applicableLooking for participantsNCT06171360
What this trial is testing

The Gut Microbiome in Hormone Receptor-positive HER2-negative Breast Cancer Treated With CDK4/6 Inhibitors

Who this might be right for
Breast Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain 100
Large-scale testing (Phase 3)Not Yet RecruitingNCT07382687
What this trial is testing

Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype

Who this might be right for
Breast Cancer
Fudan University 248
Not applicableUnknownNCT04579484
What this trial is testing

Determinants of Acquired Endocrine Resistance in Metastatic Breast Cancer: A Pilot Study

Who this might be right for
Metastatic Breast Cancer
Sunnybrook Health Sciences Centre 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03439735
What this trial is testing

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC

Who this might be right for
Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 45
Large-scale testing (Phase 3)Not Yet RecruitingNCT07544056
What this trial is testing

BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Who this might be right for
Locally Advanced Triple-negative Breast CancerMetastatic Triple-negative Breast Cancer
BeBetter Med Inc 446
Testing effectiveness (Phase 2)Ended earlyNCT04738292
What this trial is testing

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Who this might be right for
ER-positive Breast CancerHER2-negative Breast CancerMetastatic Cancer
University of Wisconsin, Madison 11
Testing effectiveness (Phase 2)Looking for participantsNCT06363734
What this trial is testing

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Who this might be right for
Non-small Cell Lung CancerEGFR Activating MutationCell Cycle Deregulation+1 more
Tianjin Medical University Cancer Institute and Hospital 32
Not applicableLooking for participantsNCT06925984
What this trial is testing

Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

Who this might be right for
OligoProgressive Metastatic Disease
Jules Bordet Institute 48
Large-scale testing (Phase 3)Looking for participantsNCT06680921
What this trial is testing

SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)

Who this might be right for
Locally Advanced or Metastatic Breast Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd. 460
Load More Results